Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Use of Personalized Body-Worn Alcohol Dispenser, Without Practitioner Feedback, on Bacterial Transmission, Hourly Hand Decontamination Events, and Practitioner Hand Contamination: A Multicenter Randomized Controlled Study
Dexter, Franklin , Togioka, Brandon M. , Simmons, Colby G. , Parra, Michelle C. , Koff, Matthew D. , Wanta, Brendan T., Fernandez, Patrick, Charnin, Jonathan E. , Loftus, Randy W. , Pugely, Andrew J. , Brown, Jeremiah R.

Anesthesia & Analgesia | August 4, 2025 | Volume: 142 | Issue: 1 | Pages: 205-209

10.1213/ane.0000000000007671 | PMID 40758582 Get It

Standardized Clinical Terms and Definitions for Interstitial Lung Disease: A Consensus Statement from the Fleischner Society
Ryerson, Christopher J. , Bankier, Alexander A. , Beasley, Mary Beth , Brown, Kevin M. , Colby, Thomas V. , Cottin, Vincent , Galvin, Jeffrey R. , Hariri, Lida P. , Johkoh, Takeshi , Lee, Ho Yun , Leung, Ann N. , Lynch, David A. , Müller, Néstor L. , Raoof, Suhail, Remy-Jardin, Martine , Ryu, Jay H. , Sholl, Lynette M. , Sverzellati, Nicola , Walsh, Simon , Wells, Athol U. , Bankier, Alexander , Colby, Thomas , Haramati, Linda B , Hariri, Lida P , Inoue, Yoshikazu , Lee, Ho Yun , Leung, Ann , Muller, Nestor , Nicholson, Andrew , Revel, Marie-Pierre , Remy-Jardin, Martine , Richeldi, Luca , Ryu, Jay H , Schiebler, Mark , Sholl, Lynette , White, Charles S , Johannson, Kerri A , Desai, Sujal R. , Haramati, Linda B. , Nicholson, Andrew G. , Richeldi, Luca , Travis, William D.

American Journal of Respiratory and Critical Care Medicine | August 4, 2025 | Volume: 211 | Issue: 10 | Pages: 1756-1774

10.1164/rccm.202505-1142so | PMID 40758555 Get It

Abstract Background Despite advances in diagnosis and management, the interstitial lung disease (ILD) lexicon is plagued by ambiguous and inconsistent terminology that complicates communication and impedes knowledge generation. The objective of this Fleischner Society Consensus Statement was to produce standardized terminology for ILD multidisciplinary diagnoses and major phenotypes. Methods Interviews with 10 experts were used to identify ILD clinical diagnoses and major phenotypes. The preferred terms for each entity and potential alternatives were identified, alongside the rationale for the preferred term. Entities with more than one potential term were the subject of an online modified Delphi survey posed to the 29 committee members, aiming to achieve consensus. Committee members rated their agreement with the initially preferred term—5 (strongly agree), 4 (agree), 3 (neutral/unsure), 2 (disagree), and 1 (strongly disagree)—with the option to provide additional comments. Median score ≥4 and interquartile range ≤1 were considered consensus agreement. Terms not reaching agreement were discussed by video conference, followed by an additional survey that incorporated feedback. Results From the 60 initial terms, there were two root terms that required upfront consensus before survey initiation (ILD and interstitial pneumonia) and another eight terms that had no alternative suggested by the committee or in the literature. Agreement was met by 47/50 terms (94%) in Round 1 of the survey. The three terms (6%) that did not reach agreement met agreement in Round 2. Conclusions This document provides standardized recommended terms for ILD multidisciplinary diagnoses and major phenotypes that will facilitate communication among clinicians, researchers, patients, and other stakeholders.
A Novel You Only Listen Once (YOLO) Deep Learning Model for Automatic Prominent Bowel Sounds Detection: Feasibility Study in Healthy Subjects
Kalahasty, Rohan, Yerrapragada, Gayathri, Lee, Jieun , Gopalakrishnan, Keerthy, Kaur, Avneet , Muddaloor, Pratyusha, Sood, Divyanshi, Parikh, Charmy, Gohri, Jay , Panjwani, Gianeshwaree Alias Rachna , Asadimanesh, Naghmeh, Ansari, Rabiah Aslam, Rapolu, Swetha, Karuppiah, Shiva Sankari, Dasari, Vijaya M., Helgeson, Scott A. , Arunachalam, Shivaram P. , Helgeson, Scott A , Arunachalam, S P , Panjwani, Gianeshwaree Alias Rachna , Yerrapragada, Gayathri, Ansari, Rabiah Aslam, Elangovan, Poonguzhali , Akshintala, Venkata S.

Sensors | August 4, 2025 | Volume: 25 | Issue: 15 | Pages: 4735

10.3390/s25154735 | PMID 40807899 Get It

Accurate diagnosis of gastrointestinal (GI) diseases typically requires invasive procedures or imaging studies that pose the risk of various post-procedural complications or involve radiation exposure. Bowel sounds (BSs), though typically described during a GI-focused physical exam, are highly inaccurate and variable, with low clinical value in diagnosis. Interpretation of the acoustic characteristics of BSs, i.e., using a phonoenterogram (PEG), may aid in diagnosing various GI conditions non-invasively. Use of artificial intelligence (AI) and improvements in computational analysis can enhance the use of PEGs in different GI diseases and lead to a non-invasive, cost-effective diagnostic modality that has not been explored before. The purpose of this work was to develop an automated AI model, You Only Listen Once (YOLO), to detect prominent bowel sounds that can enable real-time analysis for future GI disease detection and diagnosis. A total of 110 2-minute PEGs sampled at 44.1 kHz were recorded using the Eko DUO® stethoscope from eight healthy volunteers at two locations, namely, left upper quadrant (LUQ) and right lower quadrant (RLQ) after IRB approval. The datasets were annotated by trained physicians, categorizing BSs as prominent or obscure using version 1.7 of Label Studio Software®. Each BS recording was split up into 375 ms segments with 200 ms overlap for real-time BS detection. Each segment was binned based on whether it contained a prominent BS, resulting in a dataset of 36,149 non-prominent segments and 6435 prominent segments. Our dataset was divided into training, validation, and test sets (60/20/20% split). A 1D-CNN augmented transformer was trained to classify these segments via the input of Mel-frequency cepstral coefficients. The developed AI model achieved area under the receiver operating curve (ROC) of 0.92, accuracy of 86.6%, precision of 86.85%, and recall of 86.08%. This shows that the 1D-CNN augmented transformer with Mel-frequency cepstral coefficients achieved creditable performance metrics, signifying the YOLO model’s capability to classify prominent bowel sounds that can be further analyzed for various GI diseases. This proof-of-concept study in healthy volunteers demonstrates that automated BS detection can pave the way for developing more intuitive and efficient AI-PEG devices that can be trained and utilized to diagnose various GI conditions. To ensure the robustness and generalizability of these findings, further investigations encompassing a broader cohort, inclusive of both healthy and disease states are needed.
Impact of Extending Beta-Lactam Infusions on IV Access Requirements
Kooda, Kirstin , Nelson, Julia, Ausman, Sara , Warfield, Micaela , Zhao, Yanjun , Frazee, Erin N. , Group, on behalf of the Beta Lactam Optimization and Outcomes Management (BLOOM) Study, Kooda, Kirstin J, Abu Saleh, Omar M, Warfield, Micaela N, Nelson, Julia, Ausman, Sara E , Rivera, Christina G. , Saleh, Omar M. Abu, Rule, Andrew D. , Stevens, Ryan W. , Group, on behalf of the Beta Lactam Optimization and Outcomes Management (BLOOM) Study

Critical Care Explorations | August 4, 2025 | Volume: 7 | Issue: 8 | Pages: e1299

10.1097/cce.0000000000001299 | PMID 40758359 Get It

This study aimed to determine if extended infusion (EI; over > 3 hr) beta-lactam therapy increased IV access requirements compared with traditional dosing (TD; over 30 min). Eighty-six adult ICU patients treated with TD anti-pseudomonal beta-lactams who underwent therapeutic drug monitoring (TDM) were included. Patients who transitioned from TD to EI after TDM (EI group) were matched 1:1 to patients who remained on TD. In the primary analysis, the median (interquartile range) total number of lumens in the 24 hours before TDM compared with the 48 hours after TDM were similar between groups (pre: TD 3 [2–5] vs. EI 4 [3–5]; p = 0.22 and post: TD 3 [2–4] vs. EI 4 [3–5]; p = 0.05). Delivery of beta-lactams via EI was not associated with a need for more IV access. Practical challenges such as access should not limit use of EI beta-lactams when indicated.
Outcomes of Venovenous Extracorporeal Membrane Oxygenation for Pneumocystis jirovecii Pneumonia: A Multicenter Retrospective Case Series
Pulsipher, Aaron M. , Henry, Kyle, Cartin‐Ceba, Rodrigo , Lee, Augustine S. , Patel, B. M. , Miller, Brittany, Thompson, Emily , Sen, Ayan , Ham, Kealy R., Lee, Augustine, Thompson, Emily R , Pulsipher, Aaron M , Vikram, Holenarasipur R. , Gotway, Michael B. , Limper, Andrew H. , Miller, Brittany

Critical Care Explorations | August 4, 2025 | Volume: 7 | Issue: 8 | Pages: e1296

10.1097/cce.0000000000001296 | PMID 40758332 Get It

Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection increasingly recognized among non-HIV immunocompromised patients. In severe cases progressing to acute respiratory distress syndrome, venovenous extracorporeal membrane oxygenation (VV-ECMO) may serve as a rescue therapy. We conducted a retrospective multicenter review of 10 adult patients with proven or probable PCP who received VV-ECMO between 2017 and 2024. Seven of 10 patients survived to discharge, including all three HIV-positive patients and 4 of 7 non-HIV immunocompromised patients. The mean Respiratory ECMO Survival Prediction Score was –1.5, corresponding to a predicted survival of 33–57%. Multiorgan dysfunction was common, including renal failure requiring dialysis in 6 of 10 patients, need for neuromuscular blockade in 8 of 10, and pulmonary vasodilator use in 8 of 10. Despite high acuity and prolonged ECMO support, outcomes were favorable. These findings suggest that VV-ECMO may be a viable salvage therapy for select patients with severe PCP, including those without HIV.
Prostaglandin E2 as a Mechanistic Biomarker of Chronic Pancreatitis
Saloman, Jami L. , Jefferson, Bahiyyah, Fisher, William E., Fogel, Evan L. , Hart, Phil A. , Park, Walter G. , Vege, Santhi Swaroop , Yadav, Dhiraj , Topazian, Mark , Conwell, Darwin L. , Saloman, Jami L , Han, Samuel , Li, Liang

Clinical and Translational Gastroenterology | August 4, 2025 | Volume: 16 | Issue: 10 | Pages: e00897

10.14309/ctg.0000000000000897 | PMID 40758192 Get It

INTRODUCTION: Chronic pancreatitis (CP) is a disease associated with chronic inflammation, fibrosis, and pain. There is a lack of tools available that facilitate early diagnosis, when intervention could prevent irreversible damage. Pilot data suggested prostaglandin E2 (PGE2) as a candidate biomarker for early CP. PGE2 activates signaling pathways that promote inflammation, pain, and fibrosis. METHODS: We assessed PGE2, metabolites, and downstream targets in pancreatic fluid collected endoscopically 0–10 (n = 110) and 10–20 (n = 111) minutes after intravenous secretin administration. PGE2 and metabolites were measured in plasma (n = 75) and urine (n = 71) from the same subjects. Subjects were enrolled in the PROCEED study and classified symptomatic controls, acute/recurrent acute pancreatitis (AP/RAP), or CP. RESULTS: A significant main effect was detected in 10–20 minutes pancreas fluid ( P = 0.027) and plasma ( P = 0.046); post hoc testing showed PGE2 was lower in the AP/RAP group compared with symptomatic controls. There was also trend toward lower PGE2 in urine ( P = 0.062). To elucidate the active downstream pathways, calcitonin gene-related peptide, substance P, and matrix metalloproteinases (MMPs) 1, 2, 3, 7, 9, and 13 were measured in pancreas fluid. A significant difference between the 3 groups was detected for both MMP7 and MMP9. MMP7 was elevated in individuals with CP vs AP/RAP ( P = 0.012) for samples collected early but both time points for MMP9 ( P = 0.027, P = 0.002). DISCUSSION: While PGE2 is detectable in pancreas fluid, these data suggest that it may not be sensitive enough to distinguish between AP/RAP and CP. However, MMPs may distinguish between stages of pancreatitis and require further testing as potential diagnostic biomarkers.
Up-to-date review on concomitant mitral transcatheter edge-to-edge repair and left atrial appendage occlusion
Prosperi-Porta, Graeme, Hibbert, Benjamin , Abdel‐Razek, Omar , Al-Abcha, Abdullah, Hibbert, Benjamin , Prosperi‐Porta, Graeme , Al‐Abcha, Abdullah , Simard, Trevor

Future Cardiology | August 4, 2025 | Volume: 22 | Issue: 1 | Pages: 65-73

10.1080/14796678.2025.2543184 | PMID 40757898 Get It

Low‐Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double‐Blind Randomised Placebo‐Controlled Trial
Meersseman, Philippe , Hernández‐Tejero, María , Díaz, Juan Manuel , Wauters, Joost , Aziz, Fátima, Ceunen, Helga, Prado, Verónica , Langouche, Lies , Arteaga, Mireya , Lleixà, Marc , Zapatero, Juliana, Toapanta, David , Wilmer, Alexander , Langouche, Lies , Arteaga, Mireya , Acevedo, Juan , Lleixa, Marc , Toapanta, David , Wilmer, Alexander , Fernandez, Javier , Diaz, Juan Manuel, Hermans, Greet , Ceunen, Helga, Zapatero, Juliana, Arroyo, Vicente

Liver International | August 4, 2025 | Volume: 45 | Issue: 9 | Pages: No page available

10.1111/liv.70257 | PMID 40757786 Get It

ABSTRACT Background and Aims Steroid supplementation remains controversial in septic shock, partly due to the heterogeneity of the populations studied. Cirrhotic patients with sepsis frequently develop relative adrenal insufficiency, showing poor response to vasopressors and poor prognosis. Early administration of low‐dose hydrocortisone might facilitate shock reversal and reduce mortality in this population. Methods Double‐blind, randomised, placebo‐controlled multicentre trial, enrolling adult cirrhotic patients with septic shock. Patients were assigned to receive i.v. hydrocortisone (100 mg followed by a continuous infusion of 200 mg/24 h) or placebo, for at least 3 days, followed by a tapering period of 3–7 days, depending on the time of shock resolution. Primary endpoint was 28‐day all‐cause mortality. Results After enrolment of 83 patients the trial was stopped early due to slow inclusions. Most patients required low‐to‐moderate doses of vasopressors. There was no difference in 28‐day mortality (35% vs. 39.5%; p = 0.84) between hydrocortisone and placebo groups. Shock resolution (85% vs. 72.1%; p = 0.25) and days to shock resolution [3 days (2.2–4; IQR) vs. 4 (2–7.5; IQR)] were also similar between groups. More patients receiving placebo died of refractory shock (47.6% vs. 8.7%). No significant differences between treatment arms were observed in shock relapse, new shock episodes or bacterial or fungal superinfections during hospital stay. Hypo‐ and hyperglycaemias were more frequent in the hydrocortisone arm. Severity of ACLF at inclusion and inadequacy of empirical antibiotic therapy (HR = 6.40; 95% CI: 3.21–12.79) independently predicted 28‐day mortality. Conclusions Supplemental hydrocortisone did not improve short‐term survival in cirrhotic patients with septic shock requiring low‐to‐moderate doses of vasopressors. Trial Registration S‐number University Hospitals Leuven, Belgium: S55168; EUDRACT: 2010–024273‐38; Clinicaltrials.gov id: NCT02602210
Transplant Pharmacist Intervention During Pediatric Care Center Transfers: An Unaddressed Gap
Huntsman, R. G. , Fenske, Molly , Lemke, Adley , Schueler, Kerry, DiCarlo, Michele , Kolbet, Karen , McCord, Molly, Rosier, Ashley S. , Johnson, Jonathan N. , Ameduri, Rebecca , Bernard, Stacy A. , Lemke, Adley I , Fenske, Molly W , Huntsman, Rachel

Pediatric Transplantation | August 4, 2025 | Volume: 29 | Issue: 6 | Pages: No page available

10.1111/petr.70155 Get It

ABSTRACT Background Risk for medication error increases during care transitions. Error susceptibility increases in pediatrics due to age and weight‐based dosing. Governing bodies acknowledge errors endanger patients, and transplant pharmacotherapy experts are mandated by the Center for Medicare and Medicaid Services (CMS). Pharmacist‐led medication histories reduce errors; however, pharmacists' roles in the transitions of care between transplant centers are unaddressed by CMS. We assessed the impact of transplant pharmacist involvement in medication histories for pediatrics transitioning between transplant centers. Methods Pediatric patients pre‐ or post‐heart transplant transitioning to our center were proactively identified. Transplant pharmacists conducted medication histories by phone with caregivers and tracked discrepancies between existing medication lists and interview responses. Descriptive statistical analyses were completed. Results Of 27 patients identified, seven caregivers were uncontactable, one declined participation, and 19 underwent transplant pharmacist medication history. Medication list errors were detected in 100% of patients ( n = 19), with a median [IQR] of 5 [3–11] issues per patient. Of 122 issues, 72 (59%) were inaccurate or missing data, 17.2% ( n = 21) listed stopped drugs, 9.8% ( n = 12) revealed incorrect administration routes, 7.4% ( n = 9) were duplicate medications, and 6.6% ( n = 8) of errors were medications needing to be added. Corrections included updating 84 inaccuracies (68.8%); removing/adding drugs (30 [24.6%] and 8 [6.6%], respectively); and team communication. Conclusions Complex dosing strategies in pediatrics confer error vulnerability. Designing transition of care processes with transplant pharmacist involvement in medication histories can assist in ensuring medication list accuracy, thereby improving pediatric patient safety.
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder
Paner, Gladell P. , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang, Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Reis, Henning , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular

Advances in Anatomic Pathology | August 4, 2025 | Volume: 33 | Issue: 1 | Pages: 1-16

10.1097/pap.0000000000000510 | PMID 40757456 Get It

The Dublin ISUP Consensus Conference covered the proceedings on the best practice recommendations on nonurachal glandular lesions of the urinary bladder, bladder diverticular cancers, and molecular features of bladder and urachal glandular lesions. The conference proceedings on urachal neoplasms (except for their molecular features) are published elsewhere. The rationale for convening this conference was the lack of structured and consented pathologic recommendations in these rare lesions. Consensus by participants was reached on the following statements: (1) intestinal metaplasia with dysplasia is considered to be a precursor to primary bladder adenocarcinoma; (2) dysplasia arising from cystitis glandularis should be reported in terms of focality (focal or nonfocal) and grade (low or high); (3) the term “adenocarcinoma” should only be used for carcinomas showing pure (nonurothelial) morphology and should not be used interchangeably in urothelial carcinoma with “glandular differentiation” because of the pathobiological differences and management implications; (4) the different histologic subtypes of bladder adenocarcinoma should be specified in the report; (5) immunohistochemistry has an ancillary role in the work up of bladder adenocarcinoma versus gastrointestinal or Müllerian-type adenocarcinomas; (6) lymphovascular invasion should be included as a parameter when reporting bladder adenocarcinoma; (7) representative or targeted sampling will be sufficient for bladder diverticulum resection specimens; and (8) molecular analysis in genomic profiling should be performed only in advanced or metastatic bladder and urachal adenocarcinomas for targetable therapy. This report on glandular (nonurachal) lesions of the bladder from the Dublin ISUP consensus conference will serve as a best practice recommendation and as a guide for future research on these relatively rare lesions.